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Abstract
Sentinel node mapping is an integral part of regional lymph node staging in many solid tumors and plays an important role in 
surgical oncology. This technique has been used with excellent results for non-melanoma skin cancers including Merkel Cell 
Carcinoma (MCC). In the current study, we reported our first MCC patient who underwent successful sentinel node mapping. 
We also reviewed the available literature regarding the prognostic significance of sentinel node mapping in cN0 MCC patients.
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Background
Merkel Cell Carcinoma (MCC) is a rare aggressive neuroen-
docrine skin tumor with high rate of recurrence and distant metas-
tasis [1]. Pathological status of regional lymph nodes is one of the 
most important prognostic factors in MCC. Patients with clinically 
involved regional nodes have far worse prognosis compared with 
cN0 patients [2, 3].
However there is a group of cN0 patients with occult lymph node 
metastasis which also have poor prognosis and outcome. Sentinel 
node mapping is an important technique for regional lymph node 
staging in many solid tumors which has also been used for MCC [4].
We reported a cN0 MCC of the upper limb which was treated 
with sentinel node mapping and briefly reviewed the available 
literature regarding the prognostic importance of sentinel node 
mapping in MCC.
Case report
A 65-year-old male presented with a 0.8 cm painless erythema-
tous mass over the lateral aspect of the left elbow. The mass had 
been present for more than 1 year and slowly growing. He didn’t 
have any history of trauma or previous skin lesions. He didn’t have 
any history of malignancy.
The patient underwent excisional biopsy of the lesions. 
Hematoxylin and Eosin and cytokeratin 20 staining lead to the 
diagnosis of MCC. 
The patient was referred to the nuclear medicine department 
for sentinel node biopsy the morning of the surgery. The patient 
received two injections of 0.5 mCi/0.2 mL 99mTc-phytate subcuta-
neously around the scar of the tumor biopsy, 30 minutes before 
surgery. Ten minutes post-injection, lymphoscintigraphy images of 
the patient was performed (ANT-POST views, 5 minutes/view, using 
99mTc photopeak and a dual head variable angle gamma camera 
(E.CAM Siemens) equipped with high resolution low energy col-
limator). Hue of the patient (scatterogram) was imaged simultane-
ously by the technique of Momennezhad et al. [5]. Scatterogram 
is imaging of the scatter photons of the Tc-99m simultaneous with 
the original lymphoscintigraphy images. In this technique, no ad-
ditional time or radiation is needed and a hue of the patient can 
be imaged. As scatterogram can be done without any additional 
time, radiation and cost; it can be recommended with all planar 
lymphoscintigraphy imaging. 
Lymphoscintigraphy images of the patient showed a single 
sentinel node in the axillary region (Figure 1). Intra-operatively the 
tumor site was excised with a wide margin and an axillary sentinel 
node was harvested by a gamma probe (EUROPROBE, France). 
The sentinel node was not pathologically involved by frozen section 
examination and axillary dissection was not performed. Permanent 
H&E examination of the sentinel nodes was done after serial sec-
tioning and was also pathologically negative. 
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The patient underwent local radiotherapy for the primary site 
of the tumor. At 7 months follow up the patient didn’t have any 
evidence of local or regional recurrence.
Literature review and discussion
Sentinel node mapping is the standard method of regional 
lymph node staging in breast cancer and melanoma [6, 7]. Its ap-
plication in other solid tumors such as gynecological and urological 
cancers is growing with very promising results [8, 9]. 
Lymphatic mapping and sentinel node biopsy has also become 
very common in the high risk squamous cell carcinoma (SCC) of 
the skin [10, 11] including SCC of the genital area [12, 13]. 
Sentinel node mapping for MCC has been performed with 
excellent accuracy since 1998 [14]. By identifying subgroup of 
patients with regional lymph node involvement in clinically node 
negative patients, sentinel node mapping can help planning treat-
ment in MCC patients. Our department has an extensive experi-
ence in sentinel node mapping in different solid tumors since ten 
years ago [15]. The current case was the first MCC patient who 
underwent sentinel node mapping in our department. An axillary 
sentinel node could be harvested successfully intra-operatively and 
was not pathologically involved. Axillary node dissection was not 
performed and the patient didn’t receive any specific treatment for 
axillary area. Thus far the patient is recurrence free.
Nuclear medicine plays a pivotal role in the lymphatic map-
ping of solid tumors and nuclear physicians are the integral part 
of sentinel node mapping team. Pre-operative lymphoscintigraphy 
is also an integral part of lymphatic mapping in surgical oncology. 
Lymphoscintigraphy can help the surgeons to plan the surgery 
due to sentinel node localization before surgery, can identify the 
unusual locations of sentinel nodes and may decrease detection 
failure and false negative rate [16, 17]. 
Thus far three systematic reviews have addressed lymphatic 
mapping in MCC [4, 18]. Mehrany et al. in the 2002 systematic 
review gathered all cases of sentinel node mapping in MCC by com-
prehensive search of the literature. They could gather information 
of 60 patients, 67% of whom had pathologically negative sentinel 
nodes. These sentinel node negative patients had no evidence 
of regional nodal recurrence at follow up visits (no false negative 
case) [18]. In the 2006 systematic review, Gupta et al. gathered 
information of 122 MCC patients with lymphatic mapping. They 
reported that sentinel node mapping upstaged 39 patients (32%) 
due to pathologically involved sentinel node. This finding has an im-
portant clinical implication as these patients may not have received 
treatment to the involved node bed. Recurrence rate (overall re-
gional and distant) was three times higher in sentinel node positive 
patients as compared with the sentinel node negative ones [4]. The 
last systematic review by Sadeghi et al. in 2014 showed the prog-
nostic importance of SLN mapping in cN0 MCC patients as sentinel 
node mapping can improve disease free and overall survival in cN0 
MCC patients as compared with nodal observation [19].
Thus far, six studies reported survival benefit of sentinel node 
mapping in cN0 MCC patients [20–25]. Table 1 summarizes the 
characteristics of these studies in addition to their main prognostic 
findings. Overall, these prognostic studies showed that operative 
Figure 1. Lymphoscintigraphy images of the patient. The lower row images are scatterograms of the corresponding upper row lymphoscintigrams. 
A sentinel node could be identified in the left axilla. Injection site is out of the field of imaging
Nuclear Medicine Review 2016, Vol. 19, No. 1
www.nmr.viamedica.pl44
Case  
report
nodal staging with sentinel node biopsy is associated with improved 
overall and disease free survival as compared with nodal obser-
vation in cN0 MCC patients. In addition, 3 studies evaluated the 
prognostic significance of pathological involvement of the sentinel 
nodes in MCC [26–28] . Brief prognostic data of these studies are 
available in Table 2. 
In conclusion, sentinel node mapping is an important method 
for regional lymph node staging in cN0 MCC patients. Medical 
literature supports that sentinel node mapping in cN0 MCC pa-
tients is associated with improved overall and disease free survival. 
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